Which has stronger earnings and valuation, KZIA or RANI?

Novogen has higher earnings, but lower revenue than Rani Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $42K 521.48 -$13.41M N/A N/A Rani Therapeutics $1.63M 58.62 -$29.67M -$0.41 N/A

Is KZIA or RANI more profitable?

Novogen's return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Rani Therapeutics N/A -206.46% -83.95%

Do analysts recommend JATT or KZIA?

Novogen has a consensus target price of $25.80, suggesting a potential upside of 94.72%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has stronger earnings and valuation, JATT or KZIA?

JATT Acquisition has higher earnings, but lower revenue than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Novogen $42K 521.48 -$13.41M N/A N/A

Is JATT or KZIA more profitable?

Novogen's return on equity of 0.00% beat JATT Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets JATT Acquisition N/A -49.58% 2.84% Novogen N/A N/A N/A

Do analysts prefer KZIA or ICCC?

Novogen presently has a consensus target price of $25.80, suggesting a potential upside of 94.72%. Given Novogen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Novogen is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, KZIA or ICCC?

ImmuCell has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $42K 521.48 -$13.41M N/A N/A ImmuCell $27.64M 3.37 -$1.04M -$0.06 N/A

Is KZIA or ICCC more profitable?

Novogen has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. Novogen's return on equity of 0.00% beat ImmuCell's return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A ImmuCell -1.82% -1.88% -1.22%

Which has stronger earnings and valuation, RNTX or KZIA?

Novogen has higher revenue and earnings than Rein Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rein Therapeutics N/A N/A -$49.87M -$1.90 N/A Novogen $42K 521.48 -$13.41M N/A N/A

Is RNTX or KZIA more profitable?

Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A N/A -68.14% Novogen N/A N/A N/A

Which has preferable earnings & valuation, CRDF or KZIA?

Novogen has lower revenue, but higher earnings than Cardiff Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cardiff Oncology $590K 147.17 -$45.85M -$0.67 N/A Novogen $42K 521.48 -$13.41M N/A N/A

Novogen (KZIA) Competitors

$13.25 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$13.40 +0.15 (+1.16%)

As of 07/2/2026 07:59 PM Eastern

Compare

KZIA vs. RANI, JATT, ICCC, RNTX, and CRDF

Should you buy Novogen stock or one of its competitors? MarketBeat compares Novogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novogen include Rani Therapeutics (RANI), JATT Acquisition (JATT), ImmuCell (ICCC), Rein Therapeutics (RNTX), and Cardiff Oncology (CRDF). These companies are all part of the "pharmaceutical products" industry.

How does Novogen compare to Rani Therapeutics?

Novogen (NASDAQ:KZIA) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Novogen has higher earnings, but lower revenue than Rani Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$42K	521.48	-$13.41M	N/A	N/A
Rani Therapeutics	$1.63M	58.62	-$29.67M	-$0.41	N/A

In the previous week, Novogen and Novogen both had 1 articles in the media. Novogen's average media sentiment score of 1.00 beat Rani Therapeutics' score of 0.00 indicating that Novogen is being referred to more favorably in the media.

Company	Overall Sentiment
Novogen	Positive
Rani Therapeutics	Neutral

Novogen's return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Rani Therapeutics	N/A	-206.46%	-83.95%

Novogen presently has a consensus target price of $25.80, indicating a potential upside of 94.72%. Rani Therapeutics has a consensus target price of $8.75, indicating a potential upside of 1,034.45%. Given Rani Therapeutics' higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

30.9% of Novogen shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Novogen has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Summary

Novogen beats Rani Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Novogen compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

In the previous week, JATT Acquisition and JATT Acquisition both had 1 articles in the media. Novogen's average media sentiment score of 1.00 beat JATT Acquisition's score of 0.00 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
JATT Acquisition	Neutral
Novogen	Positive

JATT Acquisition has higher earnings, but lower revenue than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Novogen	$42K	521.48	-$13.41M	N/A	N/A

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Comparatively, 1.0% of Novogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Novogen's return on equity of 0.00% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Novogen	N/A	N/A	N/A

Novogen has a consensus target price of $25.80, suggesting a potential upside of 94.72%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Novogen beats JATT Acquisition on 6 of the 10 factors compared between the two stocks.

How does Novogen compare to ImmuCell?

Novogen (NASDAQ:KZIA) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

In the previous week, Novogen had 1 more articles in the media than ImmuCell. MarketBeat recorded 1 mentions for Novogen and 0 mentions for ImmuCell. Novogen's average media sentiment score of 1.00 beat ImmuCell's score of 0.00 indicating that Novogen is being referred to more favorably in the media.

Company	Overall Sentiment
Novogen	Positive
ImmuCell	Neutral

Novogen has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. Novogen's return on equity of 0.00% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
ImmuCell	-1.82%	-1.88%	-1.22%

ImmuCell has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$42K	521.48	-$13.41M	N/A	N/A
ImmuCell	$27.64M	3.37	-$1.04M	-$0.06	N/A

30.9% of Novogen shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 5.7% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Novogen presently has a consensus target price of $25.80, suggesting a potential upside of 94.72%. Given Novogen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Novogen is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Novogen has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Summary

Novogen beats ImmuCell on 11 of the 14 factors compared between the two stocks.

How does Novogen compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Rein Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 606.00%. Novogen has a consensus price target of $25.80, suggesting a potential upside of 94.72%. Given Rein Therapeutics' higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-68.14%
Novogen	N/A	N/A	N/A

Rein Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Novogen has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

In the previous week, Rein Therapeutics and Rein Therapeutics both had 1 articles in the media. Novogen's average media sentiment score of 1.00 beat Rein Therapeutics' score of 0.00 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Rein Therapeutics	Neutral
Novogen	Positive

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 1.5% of Rein Therapeutics shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Novogen has higher revenue and earnings than Rein Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A
Novogen	$42K	521.48	-$13.41M	N/A	N/A

Summary

Novogen beats Rein Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Novogen compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Cardiff Oncology has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market. Comparatively, Novogen has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 8.5% of Cardiff Oncology shares are held by company insiders. Comparatively, 1.0% of Novogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Novogen has lower revenue, but higher earnings than Cardiff Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	147.17	-$45.85M	-$0.67	N/A
Novogen	$42K	521.48	-$13.41M	N/A	N/A

Cardiff Oncology currently has a consensus target price of $9.80, suggesting a potential upside of 671.65%. Novogen has a consensus target price of $25.80, suggesting a potential upside of 94.72%. Given Cardiff Oncology's higher probable upside, analysts clearly believe Cardiff Oncology is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Novogen has a net margin of 0.00% compared to Cardiff Oncology's net margin of -8,527.43%. Novogen's return on equity of 0.00% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-8,527.43%	-95.51%	-71.47%
Novogen	N/A	N/A	N/A

In the previous week, Novogen had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 1 mentions for Novogen and 0 mentions for Cardiff Oncology. Novogen's average media sentiment score of 1.00 beat Cardiff Oncology's score of 0.00 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiff Oncology	Neutral
Novogen	Positive

Summary

Novogen beats Cardiff Oncology on 11 of the 14 factors compared between the two stocks.

Get Novogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KZIA vs. The Competition

Export

Metric	Novogen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$21.91M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	N/A	21.61	28.02	24.70
Price / Sales	521.48	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	-2.48	8.66	10.96	6.46
Net Income	-$13.41M	$23.81M	$3.57B	$337.01M
7 Day Performance	-8.18%	3.39%	2.12%	1.69%
1 Month Performance	20.56%	10.81%	5.25%	3.81%
1 Year Performance	94.25%	62.61%	33.29%	23.90%

Novogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KZIA Novogen	2.5832 of 5 stars	$13.25 flat	$25.80 +94.7%	+94.3%	$21.91M	$42K	N/A	12	Positive News Analyst Forecast Gap Up
RANI Rani Therapeutics	1.8945 of 5 stars	$0.76 -0.6%	$8.75 +1,050.7%	+43.4%	$94.73M	$1.63M	N/A	110
JATT JATT Acquisition	N/A	$11.36 -3.3%	N/A	+950.0%	$91.16M	N/A	N/A	3	Gap Down High Trading Volume
ICCC ImmuCell	0.7057 of 5 stars	$10.05 +1.4%	N/A	+53.2%	$89.65M	$27.64M	N/A	70	Positive News High Trading Volume
RNTX Rein Therapeutics	3.6668 of 5 stars	$1.04 flat	$7.00 +573.1%	-34.3%	$88.96M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KZIA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novogen (KZIA) Competitors

KZIA vs. RANI, JATT, ICCC, RNTX, and CRDF

How does Novogen compare to Rani Therapeutics?

Summary

How does Novogen compare to JATT Acquisition?

Summary

How does Novogen compare to ImmuCell?

Summary

How does Novogen compare to Rein Therapeutics?

Summary

How does Novogen compare to Cardiff Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novogen (KZIA) Competitors

KZIA vs. RANI, JATT, ICCC, RNTX, and CRDF

How does Novogen compare to Rani Therapeutics?

Which has stronger earnings and valuation, KZIA or RANI?

Does the media refer more to KZIA or RANI?

Is KZIA or RANI more profitable?

Do analysts rate KZIA or RANI?

Do institutionals & insiders have more ownership in KZIA or RANI?

Which has more risk and volatility, KZIA or RANI?

Summary

How does Novogen compare to JATT Acquisition?

Does the media prefer JATT or KZIA?

Which has stronger earnings and valuation, JATT or KZIA?

Do insiders and institutionals hold more shares of JATT or KZIA?

Is JATT or KZIA more profitable?

Do analysts recommend JATT or KZIA?

Summary

How does Novogen compare to ImmuCell?

Does the media refer more to KZIA or ICCC?

Is KZIA or ICCC more profitable?

Which has better valuation and earnings, KZIA or ICCC?

Do institutionals & insiders hold more shares of KZIA or ICCC?

Do analysts prefer KZIA or ICCC?

Which has more volatility and risk, KZIA or ICCC?

Summary

How does Novogen compare to Rein Therapeutics?

Do analysts rate RNTX or KZIA?

Is RNTX or KZIA more profitable?

Which has more volatility and risk, RNTX or KZIA?

Does the media prefer RNTX or KZIA?

Do institutionals & insiders hold more shares of RNTX or KZIA?

Which has stronger earnings and valuation, RNTX or KZIA?

Summary

How does Novogen compare to Cardiff Oncology?

Which has more volatility & risk, CRDF or KZIA?

Do insiders & institutionals have more ownership in CRDF or KZIA?

Which has preferable earnings & valuation, CRDF or KZIA?

Do analysts rate CRDF or KZIA?

Is CRDF or KZIA more profitable?

Does the media refer more to CRDF or KZIA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools